Home › Marginal Zone Lymphoma › New York
Marginal Zone Lymphoma clinical trials in New York
16 studies for Marginal Zone Lymphoma are looking for participants at sites in New York.
Cities in New York
- New York City11 studies
- Greenburgh5 studies
- Queens5 studies
- New Rochelle4 studies
- Staten Island4 studies
- Buffalo4 studies
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Memorial Sloan Kettering Suffolk - Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07231952A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Roswell Park Comprehensive Cancer Center, Buffalo
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Epco, Zanu, Ritux for R/R FL or MZL
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of ARC-02 in B-cell NHL
- NYU Langone, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Stony Brook University Hospital, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06149286Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Cancer Center - Bergen, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- Weill Cornell Medical, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05700149Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
RecruitingPhase 1/2
Ages 12 to 70 · All sexes · Updated Apr 15, 2026 · NCT04491370A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT07029217Study of SGR-1505 in Mature B-Cell Neoplasms
- Roswell Park Comprehensive Cancer Center, Buffalo
- Weill Cornell, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center), Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 30, 2026 · NCT04669171AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Optum Medical Care PC, Westbury
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- and 2 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.